Cantor Fitzgerald Reiterates Overweight on Elevance Health, Maintains $600 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $600.
September 20, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating for Elevance Health, maintaining a $600 price target, indicating confidence in the company's stock performance.
The reiteration of an Overweight rating and a $600 price target by Cantor Fitzgerald suggests a positive outlook for Elevance Health's stock, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100